Results 201 to 210 of about 132,691 (312)

Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification. [PDF]

Hepatol Commun
Tseng TC, Huang SC, Kao JH.
europepmc   +1 more source

Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log₁₀ IU/mL). [PDF]

J Clin Med
Li G, Ren R, Liu J, Li J.
europepmc   +1 more source

Hepatitis B Vaccine Response in Children of Vaccinated Versus Unvaccinated Mothers: A Retrospective Cohort Study. [PDF]

J Viral Hepat
Shibli S, Suki M, Korzom T, Green MS, Safadi R.   +4 more
europepmc   +1 more source

Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. [PDF]

Euro Surveill
Furquim d'Almeida A, Ho E, Schüttler C, Beutels P, Hens N, Dudareva S, Van Damme P, Theeten H, Vanwolleghem T.   +8 more
europepmc   +1 more source

Ultrapure dialysis fluid and response to hepatitis B vaccine [PDF]

, 2002
Lang, Susanne M., Schiffl, Helmut, Wendinger, H.   +2 more
core   +1 more source

Prevalence of HBsAg in UK population

BMJ, 1987
E. H Boxall, T H Flewett
openaire   +3 more sources

Interactions between hematological biomarkers of virus infection and immune cells in mediating distant metastasis in nasopharyngeal carcinoma: insights into prognosis and induction chemotherapy administration. [PDF]

Radiol Oncol
Li S, Chen B, Cao D, Luo C, Liang Z, Kou I, Ren G, Huang W, Ruan G, Liu L, Li H, Zhu S, Fei A.   +12 more
europepmc   +1 more source

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.

Journal of Hepatology, 2013
S. Chevaliez, C. Hézode, S. Bahrami, M. Grare, J. Pawlotsky   +4 more
semanticscholar   +1 more source

Elebsiran and pegylated-IFNα: Progress toward a functional cure for chronic hepatitis B. [PDF]

JHEP Rep
Battistella S, Protzer U, Forns X.
europepmc   +1 more source

Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment-naïve HBV/HDV Co-Infected Patients. [PDF]

Liver Int
Kamal H, Jargalsaikhan G, Enkhtaivan S, Lindahl K, Hagström H, Bruce D, Ingre M, Dashtserenx B, Lkhagva-Ochir O, Ulziibadrakh T, Bungert A, Wedemeyer H, Dashdorj NB, Aleman S.   +13 more
europepmc   +1 more source